Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 8-9, 2011, Pages 534-538

  Ouelaa Benslama, Radia ^a   Emami, Shahin ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASEIN KINASE IALPHA; CASEIN KINASE IDELTA; CYCLIN D1; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOSYLTRANSFERASE INHIBITOR; IWR 1; MYC PROTEIN; PROTEIN; PYRVINIUM EMBONATE; TANKYRASE; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; WISP1 PROTEIN; WNT PROTEIN; XAV939;

CANCER CELL; CELL NUCLEUS; CELL VIABILITY; DRUG MECHANISM; ENTEROBIUS VERMICULARIS; ENZYME INHIBITION; HOMEOSTASIS; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; ANTHELMINTICS; ENTEROBIUS; HUMANS; NEOPLASMS; PYRVINIUM COMPOUNDS; TANKYRASES; WNT SIGNALING PATHWAY;

EID: 80052527426     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.03.015     Document Type: Short Survey

References (19)

1. Clevers H. Wnt/beta-catenin signalling in development and disease. Cell 2006, 127:469-480.
2. Gespach C. Stem cells and colon cancer: the questionable cancer stem cell hypothesis. Gastroenterol Clin Biol 2010, 34:653-661.
3. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
4. Le Floch N., Rivat C., De Wever O., Bruyneel E., Mareel M., Dale T., et al. The proinvasive activity of Wnt-2 is mediated through a noncanonical WNT pathway coupled to GSK-3beta and c-Jun/AP-1 signalling. FASEB J 2005, 19:144-146.
5. Taelman V.F., Dobrowolski R., Plouhinec J., Fuentealba L.C., Vorwald P.P., Gumper I., et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010, 143:1136-1148.
6. Xu C., Kim N.-G., Gumbiner B.M. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009, 8:4032-4039.
7. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signalling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
8. De Wever O., Sobczak-Thépot J., Vercoutter-Edouart A.-S., Michalski J.-C., Ouelaa-Benslama R., Stupack D.G., et al. Priming and potentiation of DNA damage responses by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol 2011, 10.3892/ijo.2011.1034.
9. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci U S A 2004, 101:12682-12687.
10. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5:91-102.
11. Thorne C.A., Hanson A.J., Schneider J., Tahinci E., Orton D., Cselenyi C.S., et al. Small-molecule inhibition of WNT signalling through activation of casein kinase 1α. Nat Chem Biol 2010, 6:829-836.
12. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes WNT signalling. Nature 2009, 461:614-620.
13. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.W., et al. Small molecule-mediated disruption of Wnt-dependent signalling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100-107.
14. Esumi H., Lu J., Kurashima Y., Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1Hpyrrol-3-yl)ethenyl]-1-me thyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 2004, 95:685-690.
15. Rosenbluth J.M., Mays D.J., Pino M.F., Tang L.J., Pietenpol J.A. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008, 28:5951-5964.
16. Emami S. Interplay between p53-family, their regulators, and PARPs in DNA repair. Clinic and Res in Hepatology Gastroentrology 2011, 35:98-104.
17. McCabe N., Cerone M.A., Ohishi T., Seimiya H., Lord C.J., Ashworth A. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009, 28:1465-1470.
18. Karlberg T., Markova N., Johansson I., Hammarström M., Schütz P., Weigelt J., et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signalling inhibitor. J Med Chem 2010, 53:5352-5355.
19. Davidson G., Shen J., Huang L., Su Y., Karaulanov E., Bartscherer K., et al. Cell cycle control of WNT receptor activation. Dev Cell 2009, 17:788-799.